In laryngeal cancer, the paucity of data does not allow for safe conclusions to be drawn: IGF1R and IGFBP3 serum levels were not identified as significant predictors of clinical outcome in the only large cohort of 540 patients with SCCHN, including 440 patients with laryngeal cancer, published to date [9]; This study, however, assessed exclusively serum levels of IGF1R and IGFBP3 and not tumoral mRNA levels or IHC expression, as in our cohort. The gene discussed is IGFBP3; the disease is laryngeal carcinoma.